KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Income (2016 - 2025)

Nektar Therapeutics has reported Net Income over the past 16 years, most recently at -$34.7 million for Q4 2025.

  • Quarterly results put Net Income at -$34.7 million for Q4 2025, down 578.35% from a year ago — trailing twelve months through Dec 2025 was -$155.3 million (down 30.59% YoY), and the annual figure for FY2025 was -$155.3 million, down 30.59%.
  • Net Income for Q4 2025 was -$34.7 million at Nektar Therapeutics, up from -$35.0 million in the prior quarter.
  • Over the last five years, Net Income for NKTR hit a ceiling of $232.8 million in Q4 2023 and a floor of -$159.1 million in Q2 2022.
  • Median Net Income over the past 5 years was -$51.7 million (2023), compared with a mean of -$58.3 million.
  • Biggest five-year swings in Net Income: soared 508.53% in 2023 and later plummeted 578.35% in 2025.
  • Nektar Therapeutics' Net Income stood at -$146.9 million in 2021, then soared by 61.21% to -$57.0 million in 2022, then soared by 508.53% to $232.8 million in 2023, then tumbled by 96.88% to $7.3 million in 2024, then plummeted by 578.35% to -$34.7 million in 2025.
  • The last three reported values for Net Income were -$34.7 million (Q4 2025), -$35.0 million (Q3 2025), and -$39.2 million (Q2 2025) per Business Quant data.